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Abstract
Background Biologic treatments for cancer continue to
place a significant economic burden on healthcare stake-
holders. Biosimilar therapies may help reduce this burden
through cost savings, thereby increasing patient access.
Objectives The purpose of this study was to collate all
published data to assess the weight of available evidence
(quantity and quality) for proposed monoclonal antibody
biosimilars and intended copies, for the treatment of
cancer.
Methods MEDLINE, Embase, and ISI Web of Science
databases were searched to September 2015. Conference
proceedings (17) were searched (2012 to July 2015).
Searches of the United States National Library of Medicine
ClinicalTrials.gov registry were also conducted. Risk of
bias assessments were undertaken to assess data strength
and validity.
Results Proposed biosimilars were identified in 23 studies
(36 publications) in oncology and ten studies in 14 publi-
cations in oncology and chronic inflammatory diseases for
bevacizumab, rituximab, and trastuzumab originators.
Based on our review of the included published studies, and
as inferred from the conclusions of study authors, the
identified proposed biosimilars exhibit close similarity to
their originators. Published data were also retrieved on
intended copies of rituximab. It remains unclear what role
these agents may have, as publications on rigorous clinical
studies are lacking for these molecules.
Conclusion While biosimilar products have the potential
to improve patient access to important biologic therapies,
robust evidence of outcomes for monoclonal antibody
biosimilars in treating cancer patients, including data from
comparative efficacy and safety trials, is not yet available
in the published literature. Significant data gaps exist,
particularly for intended copies, which reinforces the need
to maintain a clear differentiation between these molecules
and true biosimilars. As more biosimilars become available
for use, it will be important for stakeholders to understand
fully the robustness of overall evidence used to demon-
strate biosimilarity and gain regulatory approval.
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Monoclonal antibody drugs account for a significant
proportion of oncology spending in the USA and are
associated with high out-of-pocket costs for patients.
Biosimilar therapies have the potential to improve
access to these specialist oncology drugs, but
knowledge gaps may slow their adoption.
The degree of biosimilarity is ultimately determined
by regulatory authorities and is based on the totality
of evidence, which includes data on molecular and
functional characterization, other nonclinical data,
and the safety, pharmacokinetic, immunogenicity,
and efficacy clinical trial data.
Based on this review of published nonclinical and
clinical oncology studies, and as inferred from the
conclusions of study authors, proposed biosimilars of
bevacizumab, rituximab, and trastuzumab exhibit
close similarity to their originators.
However, at present, robust evidence of outcomes for
monoclonal antibody biosimilars in cancer, including
data from comparative efficacy and safety trials, is
not yet widely available in the published literature.
1 Introduction
The treatment of cancer continues to place a significant
burden on healthcare systems, with the number of cancer
cases continuing to rise due to an aging population.
Improvements in cancer diagnosis and disease manage-
ment are now extending survival, and consequently
increasing the length of time patients remain on treatment.
As a result, there is a need to control current levels of
expenditure, which are unsustainable. IMS Health recently
reported a snapshot of USA expenditure on cancer
medicines:
• Global spending on oncology and supportive care drugs
reached $100 billion in 2014, with targeted therapy
expenditures accounting for almost 50% of total
spending [1].
• Spending on oncology medicines in the USA increased
18.0% to $39.1 billion in 2015 [2].
• The fastest-growing classes of oncology therapy are
monoclonal antibodies (mAbs) and protein kinase
inhibitors; mAbs account for 35% of oncology spend-
ing due to the introduction of new treatments [2].
• USA sales figures in 2015 for two of the top 20 global
products were $6.2 billion for bevacizumab and $5.6
billion for trastuzumab [3].
Given the economic burden of cancer treatments,
healthcare systems around the world have devised a range
of methods to try to contain these costs, often resulting in
seemingly arbitrary access restrictions for patients. Patient
access to oncology medicines has been shown to vary
significantly even at the regional level [4].
A lack of consensus among healthcare professionals on
the most reliable economic drug evaluation methods to
employ has led to inconsistency in treatment guidelines.
This was demonstrated in a 2015 systematic review by
Park et al. that examined the cost-effectiveness of mAb-
based orphan drugs [5]. Patient access and reimbursement
decisions can vary greatly between regions as a conse-
quence of the different evaluation methods employed by
each agency [5].
In the USA, patient out-of-pocket costs for intravenous
cancer drugs have increased substantially in recent years, in
part due to the integration of small community-based
practices into larger hospital systems [1]. Across publicly
funded healthcare systems in Europe and other parts of the
world, a lack of reimbursement also may limit access to
effective oncology medicines, with reimbursement often
contingent upon evidence of cost effectiveness.
Biosimilars are biologics that are highly similar to bio-
logics already approved for the treatment of disease. The
first biosimilar was authorized for use in the EU in 2006. A
greater adoption of biosimilars may help to alleviate the
substantial burden on healthcare systems by stimulating
price competition and improving patient access to impor-
tant treatments [6].
Regulatory frameworks for the development of biosim-
ilars were first established by the European Medicines
Agency (EMA), followed by the World Health Organiza-
tion (WHO) and the USA Food and Drug Administration
(FDA) [7]. These regulatory frameworks specify the
requirements for approval of biosimilars, including
important foundational analytical studies to compare the
biosimilar with the approved biologic originator product. In
addition, comparative nonclinical and clinical studies are
required to assess toxicity and pharmacokinetics (PK)/
pharmacodynamics (PD), and clinical studies are required
to demonstrate an efficacy profile that is comparable to the
originator, as well as comparable safety and immuno-
genicity profiles. Robust evidence of similarity provided
from analytical, PK, and nonclinical studies form the
foundation to demonstrate the comparability of a biosimilar
to the originator and are required to meet regulatory stan-
dards and requirements for regulatory approval. It is also
important to ensure that these data are made available in
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the public domain, to facilitate awareness and under-
standing of biosimilar treatments among physicians and
other healthcare professionals.
Intended copies are copies of originator biologics that
have not undergone rigorous comparative evaluations as
stipulated by major regulatory agencies, but are neverthe-
less being commercialized by manufacturers in some
countries. There is a lack of published information about
the efficacy and safety of intended copies compared with
the originator. Furthermore, these products may have
clinically significant differences in formulation, dosages,
efficacy, and safety [8].
A comprehensive systematic literature review (SLR)
was undertaken in 2015 to identify, collate, and synthesize
all published evidence on named biosimilars and intended
copies of originator mAbs and fusion proteins [9]. The aim
of that analysis was to summarize the quantity and quality
of data available and the number and diversity of publi-
cations describing biosimilars for mAbs or fusion proteins
across all indications (including chronic inflammatory
diseases, oncology, cardiovascular and ophthalmology).
Here, we explore the findings for biosimilars indicated for
oncology disease in more detail.
2 Methods
2.1 Systematic Literature Review (SLR)
A detailed description of the methods used in this SLR can
be found in the manuscript by Jacobs et al. [9].
MEDLINE/Medline in process and Embase (sear-
ched using the OVIDSP interface), and ISI Web of
Science were searched from database inception to
September 3, 2015. The search was executed on April 27,
2015 and repeated on September 3, 2015 to capture more
recent full-text publications. The search strategy consisted
of the following: (1) terms that captured mAb and fusion
protein terms; and (2) terms that included the different
terminologies for biosimilar products, such as ‘‘biosimi-
lars,’’ ‘‘subsequent entry biologics,’’ ‘‘follow-on biolog-
ics,’’ ‘‘follow-on proteins,’’ ‘‘biocomparables,’’
‘‘biogenerics,’’ ‘‘similar biotherapeutic products,’’ and
‘‘intended copies,’’ or ‘‘biobetters’’ (which were analyzed
separately). Included publications were required to con-
tain both a ‘‘mAb’’ and/or ‘‘fusion protein’’ term and a
‘‘biosimilars’’ term. Proposed biosimilars were differenti-
ated from intended copies, based on them meeting the
established rigorous regulatory requirements for biosimi-
larity, as outlined by major regulatory health authorities
such as the EMA, FDA, WHO, Pharmaceuticals Medical
Devices Agency/Japan Ministry for Health Labor and
Welfare, Health Canada or Korean Ministry of Food and
Drug Safety (MFDS). Other markets have issued guidance
on biosimilars, although the evaluation of the biosimilar
approval pathways by regulatory authorities outside of the
major markets is considered beyond the scope of this
review. Controlled vocabulary and free-text terms were
used, and the search results were filtered using the study
designs of interest. Search results from each database
were limited to references published in the English
language.
In addition, a hand-search of relevant conference pro-
ceedings (17 conferences) was conducted for the period
January 1, 2012 to July 31, 2015 in order to capture the
latest studies not yet published as full-text articles and/or
supplement results of previously published studies (Jacobs
et al. [9]). Oncology-focused conference proceedings
(n = 10) are shown in Supplementary Table S1 (see the
electronic supplementary material, online resource 1). For
the SLR analysis, conference proceedings of interest
included disease-specific (i.e., for oncology), health eco-
nomics and outcomes research, regulatory-/payer-focused,
and manufacturing-/development-themed meetings. In
order to identify biosimilars in development that did not
appear in the published literature or in the identified con-
gresses, searches were also conducted (on September 21,
2015) using the USA National Library of Medicine Clini-
calTrials.gov registry. Hand-screening was used to identify
relevant records because of the limited extent of the sear-
ches available for ClinicalTrials.gov.
2.2 Components of the SLR
This SLR had two components: the empirical analysis,
which focused on peer-reviewed publications of analytical,
nonclinical, clinical, pharmacovigilance, and observational
empirical data; and the non-empirical analysis, which
included opinion pieces or commentaries, publications
describing product-related patient support programs, and
those on manufacturing and supply issues, which were
further classified into general thematic categories to sum-
marize key topics being published on biosimilars. These
two components were included to assess the diversity and
extent of these types of publications, as well as to identify
emergent themes and knowledge gaps in the published
literature. Empirical studies were categorized by type into
one of the following areas: ‘‘human’’ studies subdivided as
randomized controlled trials (RCTs), observational/post-
marketing studies, and health economic studies; nonclinical
(in vitro/in vivo) studies; and analytical studies. Non-em-
pirical publications were classified into one of the follow-
ing categories: manufacturing or supply topics and themes,
review articles, opinion pieces or commentaries, regula-
tory-/policy-related content, published descriptions of
product-related patient support programs, and any other
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non-empirical publication type relevant to biosimilars
meeting the inclusion criteria.
2.3 Risk of Bias (Quality) Assessment
A risk of bias assessment was undertaken for each classi-
fied study (i.e., RCTs, observational studies, studies pub-
lished in conference proceedings, and animal studies) using
a validated tool matched to study type to assess the
strength/validity of the empirical data and in accordance
with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [10, 11]. In cases
where multiple publications were retrieved for the same
study, quality assessments were only conducted on the first
original publication or first full-text publication. The
quality of RCTs was assessed using the National Institute
for Health and Care Excellence (NICE) single technology
appraisal (STA) manufacturer’s template [12] and the
Jadad scoring system [13] (Supplementary Table S2;
Supplementary Fig. S1).
Non-randomized studies were assessed using the Downs
and Black instrument [14] (Supplementary Table S3). The
Downs and Black instrument was modified to include only
the most critical qualifying parameters (12 of 26) for
quality assessment of conference proceeding abstracts
(Supplementary Table S4). Detailed parameters related to
process were excluded as these data were not available in
abstract formats, e.g., suitability of statistical method
employed. Animal studies were assessed using SYRCLE’s
risk of bias tool [15]. Conference abstracts of analytical/
nonclinical studies were not evaluated, as suitable tools
were not available at the time of analysis. Analytical and
cell-based studies published full-text were also not evalu-
ated for the same reason.
3 Results
3.1 Literature and Conference Search
A total of 768 publications relevant to the topic of
biosimilars were retained from a total of 1991 publications
identified through a title and abstract screen. Of the 768
references, 147 (19%) reported mAb biosimilars for use in
oncology. The number of publications included in the
analysis is shown in Supplementary Fig. S2. Where encore
(or duplicate) publications were retrieved for studies, the
information was compared with the original (first published
article) and excluded if no additional data were provided. If
new data were identified, encore publications were inclu-
ded along with the original publication. However, this did
not affect the overall study count. In some instances, a
biosimilar was indicated for multiple disorders or diseases.
For example, rituximab biosimilar publications were
reported for both the oncology and inflammatory disorders
categories, where relevant, as rituximab is indicated for
both therapeutic areas. Proposed biosimilars or intended
copies (i.e., where a unique identifier was provided) were
identified in 23 studies (36 publications) in oncology and
ten studies in 14 publications in oncology and chronic
inflammatory diseases (Fig. 1). In this analysis, biosimilar
trials were identified for the following indications: follic-
ular lymphoma, diffuse large B-cell lymphoma (DLBCL),
breast cancer (BC), and non-squamous non-small cell lung
cancer (NSCLC).
3.2 Preclinical Data
3.2.1 Proposed Bevacizumab Biosimilars
Published preclinical studies of proposed bevacizumab
biosimilars are presented in Table 1.
ABP 215 (Amgen) The functional similarity of ABP 215
compared with bevacizumab was assessed in vitro using
human umbilical vein endothelial cells (HUVEC) and
characterized using analytical methods [16–18]. Binding to
vascular endothelial growth factor (VEGF) and VEGF
isoforms, neonatal Fc receptor and FcgRIIa, inhibition of
proliferation, and composition between the biosimilar and
originator were similar.
Hutterer et al. investigated the structural similarity of
ABP 215 compared with bevacizumab [19]. Based on
results of structural assessment (including higher order
structure, impurities, and stability), the authors concluded
that ABP 215 was analytically highly similar to
bevacizumab.
PF-06439535 (Pfizer) The functional similarity (biological
activity or mode of action) of PF-06439535 and beva-
cizumab were assessed in vitro using cell-based assays
[20, 21]. The results of these studies indicated that PF-
06439535 was functionally similar to bevacizumab (in
HUVEC and another unspecified cell line).
Peraza et al. evaluated the functional similarity of PF-
06439535 and bevacizumab in cynomolgus monkeys [21].
The authors reported that PF-06439535 was well tolerated
and displayed similar PK properties compared with beva-
cizumab. Anti-drug antibodies (ADAbs) were not detected.
The charge heterogeneity, post-translational modifica-
tions, and hydrodynamic size heterogeneity of PF-
06439535 compared with bevacizumab were investigated
using various biochemical analytical techniques [20]. The
biochemical properties were also confirmed using com-
plementary analyses. The authors reported that PF-
06439535 displayed similar structural properties compared
with bevacizumab.
4 I. Jacobs et al.
Peraza et al. evaluated the analytical (structural) simi-
larity of PF-06439535 compared with the originator [21].
The primary sequence of PF-06439535, bevacizumab-EU,
and bevacizumab-USA was reported to be identical, as
delineated by liquid chromatography (LC)/mass spec-
trometry (MS)/MS peptide mapping.
RPH-001 (Alphamab/R-Pharm) Archuadze et al. evaluated
the PK profiles of RPH-001 and bevacizumab following a
single intravenous administration at three different doses in
cynomolgus monkeys [22]. The tested PK parameters were
reported to be comparable between RPH-001 and beva-
cizumab, and neither drug was associated with any toxicity.
3.2.2 Proposed Rituximab Biosimilars
Published preclinical studies of proposed rituximab
biosimilars are presented in Table 2.
1B8 (Center of Molecular Immunology) Dorvignit et al.
evaluated the functional comparability between 1B8 and
rituximab in human Burkitt’s lymphoma, Ramos, Daudi,
and Raji cell lines [23]. Similar biological potency was
reported [as measured by complement-dependent cytotox-
icity (CDC), antibody-dependent cellular cytotoxicity
(ADCC), and apoptosis assays].
GP2013 (Sandoz) The pharmacological comparability of
GP2013 and the originator rituximab was assessed in a
preclinical study of moderate quality (SYRCLE’s risk of
bias tool) [24]. The authors reported similar in vitro
ADCC potency when compared in a dose-response man-
ner against two lymphoma cell lines using human natural
killer (NK) cells [24]. In a separate analysis, in vivo
efficacy was demonstrated in mouse xenograft models
[25]. PK/PD (CD20 cell depletion) profiles were report-
edly comparable based on analysis in cynomolgus mon-
keys [26].
Visser et al. reported in vitro functional bioequivalence
between GP2013 and the originator rituximab in Raji B
cells [27]. The Visser et al. study did not undergo quality
assessment, because of the unavailability of suitable risk of
bias assessment tools for this type of study.
Visser et al. [27] (not assessed) and da Silva et al. [24]
(moderate quality using SYRCLE’s risk of bias tool)
compared GP2013 with rituximab using combined analyt-
ical and characterization methods. Intact mass analysis of
GP2013 revealed the same molecular mass to that of
rituximab [24–26]. The primary sequence and higher order
structure of GP2013 was reported by authors as indistin-
guishable from the originator. GP2013 and originator
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Fig. 1 Frequency of publications of reported named proposed biosimilars and ICs in oncology. IC intended copy, RCT randomized controlled
trial
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translational modifications, glycan pattern, purity, and
aggregate levels.
PF-05280586 (Pfizer) A comparative nonclinical study of
moderate quality (SYRCLE’s risk of bias tool) was con-
ducted with PF-05280586 and rituximab-EU [28–30]. CDC
assay results were reported to be similar. As part of the
same study, the safety of PF-05280586 and rituximab was
also evaluated in cynomolgus monkeys [28–30]. Both
molecules were well tolerated at doses up to 20 mg/kg.
There were no reported effects on food consumption, body
weight, body weight gain, coagulation, urinalysis, or clin-
ical chemistry parameters. No cardiac or ophthalmologic
effects were observed in the repeat-dose study (not evalu-
ated in the single-dose study). Emesis was noted in animals
administered with either PF-05280586 or rituximab (PF-
05280586 vs. control, n = 6 vs. 1; rituximab-EU vs. con-
trol, n = 7 vs. 2). The PK and PD profiles for both mole-
cules were purportedly comparable.
Karnik et al. reported biological activity data (from
in vitro cell-based assays, cell line unspecified) for PF-
05280586 versus rituximab [31]. The reported biological
activity was 93–114% for PF-05280586 versus 79–135%
for rituximab (combined range for rituximab-EU and
rituximab-USA). The Karnik et al. study did not undergo
quality assessment, because of the unavailability of suit-
able risk of bias assessment tools for this type of study at
the time of analysis.
As part of a comparative nonclinical assessment study
evaluating PF-05280586 versus rituximab, the authors
investigated the physicochemical similarity of both prod-
ucts using peptide mapping [reverse-phase (RP) high-per-
formance LC (HPLC)] [28–30]. The identity of each
peptide was confirmed by LC/MS using an ultra–high-
resolution quadrupole time-of-flight MS. The chromato-
graphic profiles of both products were reported as identical.
The totality of the data (including a separate LC/MS
analysis) confirmed identical primary sequences.
In a separate study, the primary sequence of PF-
05280586 and rituximab were confirmed using proteolytic
digests and peptide mapping via LC/MS/MS [31]. Struc-
ture, with respect to glycosylation profile and presence of
high molecular mass species (0.5–0.7 vs. 0.9–1.6 for PF-
05280586 and rituximab-EU/-USA, respectively), was
reported as similar. Product purity, charge heterogeneity,
post-translational modifications, and hydrodynamic size
heterogeneity were reportedly undertaken (individual
analyses not shown; Table 2).
RTXM83 (mAbxience) Seigelchifer et al. evaluated the
functional comparability of RTXM83 and rituximab-EU in
an unspecified cell line and in cynomolgus monkeys [32].
Similar biological potency was reported (as measured by
CDC, ADCC, and apoptosis assays). The in vitro binding
affinities to neonatal receptors were also described as simi-
lar. Data from the in vivo PK/PD study indicated that the
area under the curve (AUC), half-life, and maximum serum
concentration (Cmax) of RTXM83 were all within the pre-
specified 80–120% range of rituximab. The structural sim-
ilarity between RTXM83 and rituximab was evaluated using
mass fingerprinting and MS analysis, ultraviolet circular
dichroism spectroscopy, glycan and charge variant analysis,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
analysis, and size-exclusion HPLC analysis [32]. The results
reportedly indicated similar primary structures, comparable
secondary and tertiary structures, and similarity in the extent
of post-translational modifications. The level of purity was
observed to be comparable between the proposed biosimilar
and the originator.
3.2.3 Proposed Trastuzumab Biosimilars
Published preclinical studies of proposed trastuzumab
biosimilars are presented in Table 3.
PF-0280014 (Pfizer) Boyle et al. evaluated the biological
activity of PF-05280014 as part of a wider analytical
characterization study [33]. The mode of action of PF-
05280014 was compared with trastuzumab using in vitro
cell-binding assays (methods and cell line not described or
specified). The biological activity data indicated functional
similarity to trastuzumab-USA or trastuzumab-EU. The
statistical significance of the results was not reported. The
binding kinetics to the ligand and Fc-gamma receptor III,
involved in immune-effector functions, were also assessed
(individual data not reported). This study did not undergo
quality assessment, because no suitable risk of bias
assessment tool was available at the time of analysis.
A nonclinical comparability study between PF-05280014
and trastuzumab was conducted using in vitro structural and
functional analyses [tumor cell growth inhibition assay in
the human epidermal growth factor receptor 2 (HER2)
overexpression metastatic breast carcinoma cell line, SKBR-
3, and CDC assay], and in vivo PK and immunogenicity
assessments in male CD-1 mice [34–37]. Results of the
in vitro assessments indicated functional similarity between
PF-05280014 and trastuzumab. PK parameters [Cmax, AUC
from time zero to infinity (AUC0–?), clearance, and steady-
state volume of distribution] in mice were reported to be
similar and dose dependent. The incidence of ADAbs was
reported to be low (*10%) and similar between PF-
05280014 and trastuzumab across all dose levels tested. All
animals survived to their terminal blood collection (up to
2880 h) with no mAb-related differences in clinical signs,
mean body weight, or body weight change. The study by
Hurst et al. was considered to be of moderate quality using
SYRCLE’s risk of bias tool [34].
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An analytical study published by Boyle et al. com-
pared the structural and functional attributes of PF-
05280014 with those of trastuzumab [33]. Peptide map-
ping via LC/MS/MS confirmed identical primary struc-
tures for both PF-05280014 versus the licensed products.
Charge heterogeneity, major post-translational modifica-
tions, hydrodynamic size heterogeneity, and glycan
quantification of PF-05280014 versus trastuzumab were
evaluated using a combination of biochemical techniques,
and all analyses were reported by authors as similar
(individual data not reported). High molecular mass
species ranged from 0.2–0.4 in the PF-05280014 sample
versus 0.3–1.1 in the trastuzumab sample. This study did
not undergo quality assessment, because no suitable risk
of bias assessment tool was available at the time of
analysis.
Hurst and colleagues evaluated the structural attributes
of PF-05280014 as part of a wider nonclinical compara-
bility PK/immunogenicity assessment in mice [34–37].
Using peptide mapping, the authors reported structural
similarity, with detected peptides constituting C98% of the
amino acid sequence of trastuzumab. The complete amino
acid sequence was obtained from a separate LC/MS anal-
ysis at the subunit level, which confirmed structural simi-
larity between PF-05280014 and trastuzumab at the
primary sequence level. The study by Hurst et al. was
considered to be of moderate quality using SYRCLE’s risk
of bias tool [34].
3.3 Pharmacokinetic/Safety Data in Healthy
Subjects
3.3.1 Proposed Bevacizumab Biosimilars
Published PK/safety studies of proposed bevacizumab
biosimilars in healthy subjects are presented in Table 1.
ABP 215 (Amgen) The PK equivalence of ABP 215
(vs. bevacizumab-EU and bevacizumab-USA) was eval-
uated in healthy adult male subjects [16, 17]. The authors
reported PK equivalence of ABP 215 compared with
bevacizumab (within the prespecified equivalence criteria
of 80–125%). Similar treatment-related adverse events
(AEs) were reported for the ABP 215, bevacizumab-USA,
and bevacizumab-EU groups; no subjects developed
ADAbs. The study was considered to be of excellent
quality.
3.3.2 Proposed Rituximab Biosimilars
No published PK/safety studies in healthy subjects have
been reported for proposed biosimilars of rituximab.
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published data) have been identified for rituximab
biosimilars in rheumatoid arthritis patients [38].
3.3.3 Proposed Trastuzumab Biosimilars
Published PK/safety studies of proposed trastuzumab
biosimilars in healthy subjects are presented in Table 3.
FTMB (Allergan/Amgen) FTMB was evaluated and com-
pared with trastuzumab or placebo in a dose-escalation/
bioequivalence study in healthy male subjects (n = 118)
[39, 40]. The authors reported bioequivalence of FTMB
compared with trastuzumab [primary endpoint, AUC0–?;
ratio 0.89; 90% confidence interval (CI) 0.85–0.94]. Non-
linear, target-mediated PK were also observed. FTMB was
reported to be well tolerated up to doses of 6.0 mg/kg, with
no additional AEs occurring beyond those already docu-
mented for trastuzumab. The study was considered to be of
excellent quality, as measured by the NICE STA and Jadad
scoring tools.
PF-05280014 (Pfizer) The safety and PK properties of PF-
05280014 were evaluated and compared with trastuzumab
in a study involving 105 healthy male subjects [36, 41–44].
Reported AEs were comparable between treatments.
However, the incidence of pyrexia was higher in the PF-
05280014 arm [ten participants (28.6%); mild in all but one
participant] versus the trastuzumab arms [two to three
participants (5.7–8.6%)]. In the context of biosimilar
development, a PK similarity study is not necessarily
designed for a comparative assessment of safety. This
observation appears to be due to chance and not to any
inherent difference between PF-05280014 and trastuzumab
[43]. Only one subject was ADAb positive (ADAb?) in the
trastuzumab-EU group. The authors reported PK similarity
between PF-05280014 and trastuzumab-EU and trastuzu-
mab-USA, with a 90% CI of Cmax, time from 0 to the last
time point with quantifiable concentration (AUC0–T), and
AUC0–? within the prespecified range (80–125%) of PK
equivalence. The study was of excellent quality as mea-
sured by the NICE STA; however, using the Jadad scoring
tool, the study was considered to be only of good quality
because the method of randomization and blinding was not
described.
3.4 Clinical Evidence in Cancer Patients
3.4.1 Proposed Bevacizumab Biosimilars
Published clinical studies of proposed bevacizumab
biosimilars in cancer patients are presented in Table 1.
BCD-021 (Biocad) The PK and safety of BCD-021 were
assessed in a comparative trial involving 28 patients with
non-squamous NSCLC (stage IIIb/IV) [45]. PK analysis
revealed that 90% CIs for the ratio of geometric means of
AUC from 0 to 504 h (AUC0–504h) of bevacizumab after
single BCD-021 and bevacizumab administrations were
80.01–118.28%. The safety characteristics of BCD-021
and bevacizumab were considered equivalent by authors.
BCD-021 or bevacizumab in combination with pacli-
taxel and carboplatin was evaluated in a comparative
safety/efficacy study in 138 patients with advanced non-
squamous NSCLC (stage IIIb/IV) [46]. No statistically
significant difference was observed between groups for
overall response rate (ORR) as the primary endpoint and
other efficacy endpoints [clinical remission (CR), partial
remission (PR), stable disease, and progression rate]. The
AE profiles of BCD-021 and bevacizumab were declared
equivalent, with the majority of incident AEs reportedly
associated with chemotherapy. Binding and neutralizing
ADAbs were transient and detected only in one patient in
each group. Both studies were of excellent quality.
3.4.2 Proposed Rituximab Biosimilars
Published clinical studies of proposed rituximab biosimi-
lars in cancer patients are presented in Table 2.
BCD-020 (Biocad) BCD-020 was evaluated in a compar-
ative safety/efficacy study in 92 patients with non-Hodgkin
lymphoma (NHL) and compared with the parameters of
rituximab. The study was considered to be of excellent
quality [47–49]. ORR on day 50 ± 5 (primary endpoint) in
both arms was reported as equivalent (p = 0.8250). The
lower limit of the 95% CI for difference in proportion of
ORR between arms was –17.81%, exceeding the prede-
fined noninferiority margin (–20%). BCD-020 was con-
sidered noninferior to rituximab in all other measured
efficacy outcomes. The proportion of AEs (including
grades 3–4) was equal across both arms. The PK/PD and
immunogenicity profiles of BCD-021 were comparable
with that of the originator.
RTXM83 (mAbxience) In a PK and safety study, RTXM83
was evaluated and compared with rituximab in combina-
tion with cyclophosphamide, doxorubicin, vincristine,
prednisolone (CHOP) chemotherapy in 24 patients with
DLBCL; the study was considered to be of good quality
[50]. The authors reported comparable PK and (null)
immunogenicity profiles across both treatment arms.
SAIT101 (Samsung) The efficacy, safety, and PK/PD
parameters of SAIT101 (plus CHOP chemotherapy) were
compared with rituximab in a PK/safety study in 24
patients with DLBCL [51]. The study was considered to be
of excellent quality. SAIT101 displayed efficacy (tumor
response as measured by CR and PR parameters) and
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safety comparable with rituximab, although one case of
mortality (drug-induced pneumonitis) in the SAIT101
group was recorded. Results of the PK/PD assessment
indicated a high probability of similarity between SAIT101
and the originator.
3.4.3 Proposed Trastuzumab Biosimilars
Published clinical studies of proposed trastuzumab
biosimilars in cancer patients are presented in Table 3.
BCD-022 (Biocad) BCD-022 was evaluated and compared
with trastuzumab in a comparative PK substudy in 46
patients with HER2? metastatic BC [52]. The study was
considered to be of excellent quality using the modified
Downs and Black instrument. The primary endpoint of the
study was AUC0–504h. The authors reported PK equiva-
lence of BCD-022 compared with trastuzumab in accor-
dance with the prespecified equivalence criteria of
80–125%. BCD-022 and trastuzumab were found to be
well tolerated, without any significant differences in AE
frequency between the groups.
CT-P6 (Celltrion) CT-P6 has been investigated in a PK/
safety study in patients with HER2? metastatic BC
(n = 174) [53]. The limits of the 90% CIs for the ratio of
AUC at steady-state geometric means were reportedly
contained within the established margin (80–125%)
required for bioequivalence. There was no reported dif-
ference between other studied PK parameters. Serious AEs
were reported in 15.8% of CT-P6 and 20.9% of trastuzu-
mab patients; 2.6 and 3.0% were treatment related,
respectively. Hypersensitivity, cardiotoxicity, and infection
were noted in 1.3, 2.6, and 1.3% of CT-P6 patients and in
1.5, 7.5, and 0% of trastuzumab patients, respectively.
Results of a comparative safety/efficacy study com-
paring the efficacy and safety of CT-P6 versus trastuzu-
mab in patients (n = 475) with HER2? metastatic BC
were also published [54]. The primary outcome measure
was to demonstrate equivalence of CT-P6 and trastuzu-
mab, both given in combination with paclitaxel, in terms
of efficacy determined by ORR. A numerically greater
number of patients achieved ORR in the trastuzumab
group, compared with the CT-P6 group (62 vs. 57%,
respectively). The limits of the 95% CIs for the difference
in the proportion of responders (from the pooled inten-
tion-to-treat population) were reported to be within the
range required for bioequivalence (–0.15, 0.15). No sig-
nificant differences were observed between the two
groups in the other measured efficacy parameters. The
tolerability and safety of CT-P6 were reported as com-
parable with those of trastuzumab. Both studies were
considered to be of excellent quality.
PF-05280014 (Pfizer) Two clinical studies comparing PF-
05280014 with trastuzumab were ongoing at the time of
review. One was for first-line treatment of patients (esti-
mated n = 690) with HER2? metastatic BC and the other
for neoadjuvant treatment of operable HER2? BC (esti-
mated n = 220) [55, 56]. These studies did not undergo
quality assessment, as both were found to be trial
protocols.
3.5 Preclinical and Clinical Data for Intended
Copies of Rituximab: Kikuzubam
and RedituxTM
Published preclinical and clinical studies of rituximab
intended copies are presented in Table 4.
Kikuzubam (Probiomed) Flores-Ortiz et al. validated a
series of analytical methods for biosimilar characterization
purposes [57]. In vitro comparability assessments (CDC
and ADCC) were conducted using cell-based assays
(CD20-expressing cells and primary NK cells).
Kikuzubam displayed comparable potency to rituximab
(and intended copy RedituxTM), as indicated by the results
of the CDC and ADCC assays.
The physicochemical properties of Kikuzubam were
evaluated and compared with both RedituxTM and ritux-
imab [57]. The sequence comparability of Kikuzubam to
both comparators was confirmed using peptide mapping
(RP-HPLC). Kikuzubam and rituximab were reported to
have the identical glycoform profiles (RedituxTM displayed
heterogeneity in theoretical mass due to the C-terminal
lysine content). Significant differences were observed
among all three products with respect to charge variants, as
determined by cation exchange (CEX) and hydrophobic
interaction chromatography (HIC). Because the CEX-
HPLC technique reportedly revealed nearly two times
more acidic variants than standard HPLC methods, the
authors urged careful consideration in the chosen analytical
methods for comparability studies. The structure [deter-
mined by differential scanning calorimetry (DSC) and
matrix-assisted lasers (MALS)] and purity [determined by
capillary gel electrophoresis (CGE) and size-exclusion
chromatography (SEC)] were reportedly similar across all
three products evaluated.
RedituxTM (Dr Reddy’s Laboratories) Thakral et al.
investigated the biodistribution profile of a radiolabeled
immunoconjugate of RedituxTM [177Lu-DOTA-antiCD20
antibody-rituximab (BioSim)] in three patients with B-cell
NHL [58]. The study was considered to be of good quality
(Downs and Black score). Maximum uptake of the
radioimmunoconjugate was reportedly observed in the
liver, indicating a favorable biodistribution profile.
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Table 4 Outcomes for intended copies of rituximab















ADCC, ratio % 80–125 80–125 –
CDC (3 batches),
ratio %






































22.0 (8.0) at 96 h NR –
Kidney, %, mean
(SD)
3.8 (0.8) at 48 h NR –
Spleen, %, mean
(SD)
2.5 (1.3) at 48 h NR –
Heart, %, mean
(SD)











Apyrogenicity Pyrogen free NR –
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Table 4 continued















CR, % 82 75 p = 0.294
PR, % 13 14 p = 0.795
CR/PR ?
progressed
15 13 p = 0.805
Overall survival, % 76 66 p = 0.264
Progression-free
survival, %
81 72 p = 0.382
Safety; grades 3
and 4 (n = 30):
Febrile
neutropenia, %
20 23 p = 0.801
Mucositis, % 10 5 p = 0.385





















Pneumonia, % 0 8 –
Post-marketing/observational
(prospective)/DLBCL (133) (and
rheumatoid arthritis, scleroderma, and
dermatomyositis)
CA [62] Safety Modified
D&B: fair
Score: 4/12
All AEs, % 14.3 NA –
Chills, % 20 NA –
Headache, % 16.7 NA –
Fever, % 13.0 NA –














Mild AEs, % 90.0 NA –
Moderate AEs, % 6.7 NA –
Severe AEs, % 3.3 NA –
Mortality, % 0 NA –
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Table 4 continued






























54,236 (47,555) NA –
Cmax, lg/mL,
mean (SD)
555.74 (141.46) 408 (literature) –
Half-life, d, mean
(SD)
10.9 (8.6) 22 (literature) –
Clearance, mL/h/
kg, mean (SD)




1.3 (0.64) 2.7 (literature) –
Residence time, d,
mean (SD)
2.78 (3.08) NA –







ADCC, ratio % 80–125 80–125 –
CDC (3 batches),
ratio %
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A retrospective observational study comparing the effi-
cacy and safety of RedituxTM versus rituximab in patients
with DLBCL (n = 223) has been reported, and was con-
sidered to be of good quality (Downs and Black score)
[59–61]. CR rates were similar between RedituxTM and
rituximab originator, and overall survival at 5 years was
also reportedly comparable. There were no reported dif-
ferences in infusion-related reactions or grades 3 and 4
neutropenia and oral mucositis between the two
interventions.
A prospective observational study was conducted to
determine the causality and factors associated with onset
drug reactions during the administration of RedituxTM in
patients with cancer (excluding Hodgkin lymphoma and
chronic lymphocytic leukemia indications) [62]. The study
also assessed patients with chronic inflammatory disease,
and the analyses were pooled across indications. Of the
total number of patients (n = 133 for combined oncology
and chronic inflammatory conditions), only 19 patients
experienced AEs, of which the majority were perceived as
mild and related to the speed of infusion. The study was
considered to be of fair quality (modified Downs and Black
score).
Menon et al. evaluated the PK/PD properties of Redi-
tuxTM versus rituximab in a prospective observational
study in patients (n = 21) with DLBCL [63]. Analyses
were undertaken and compared with published data on
rituximab. The authors concluded that the PK profile and
B-cell kinetics of RedituxTM were comparable with ritux-
imab from the published literature. The study was con-
sidered to be of good quality.
Flores-Ortiz et al. compared the physicochemical
properties and biological activity of both RedituxTM and
Kikuzubam with rituximab [57]. Biological compara-
bility assessments were conducted in vitro using cell-
based assays (CD20-expressing cells and primary NK
cells). RedituxTM displayed similar biological effects to
rituximab (and Kikuzubam), as indicated by the results
of the CDC and ADCC assays (Table 4). The Florez-
Ortiz et al. study did not undergo quality assessment,
because of the unavailability of suitable risk of bias
assessment tools for this type of study at the time of
analysis.
Kumar et al. investigated the suitability (sensitivity
and specificity) of complementary assays for immuno-
genicity assessment in comparative clinical trials for
biosimilars, using RedituxTM and rituximab as prototypic
agents [64]. The study objectives were not aimed at
delineating the comparability of RedituxTM versus
rituximab. However, the authors commented that the
analytical similarity (as implied by this study) was suf-
ficient to justify the use of biosimilar drug-based assays
for immunogenicity assessment. The Kumar et al. study
did not undergo quality assessment, because of the
Table 4 continued







Analytical CA [65] Composition Not





Isotope Similar Similar –
Analytical CA [66] Composition Not
evaluatedbSDS-PAGE Similar Similar –
iCE NR NR Sig. diff.
CE NR NR Sig. diff.
CEX-HPLC NR NR Sig. diff.
ADAb antidrug antibody, ADCC antibody-dependent cellular cytotoxicity, AE adverse event, AUC area under the curve, CA conference abstract,
CDC complement-dependent cytotoxicity, CE capillary electrophoresis, CEX-HPLC cation exchange–high-performance liquid chromatography,
Cmax maximum concentration in serum, CMV cytomegalovirus, CR clinical remission, d day(s), D&B Downs and Black (tool), DLBCL diffuse
large B-cell lymphoma, IC intended copy, iCE imaged capillary electrophoresis, DSC differential scanning calorimetry, NA not applicable, NHL
non-Hodgkin lymphoma, NR not reported, PD pharmacodynamics, PK pharmacokinetics, PR partial remission, RTX rituximab, SD standard
deviation, SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis, sig. diff. significantly different
a Qualitative data for biosimilarity as stated by the corresponding study authors
b Quality assessment not conducted, because of the absence of validated tools specific for the study type, at the time of analysis
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unavailability of suitable risk of bias assessment tools
for this type of study at the time of analysis.
The immunoreactivity and apyrogenicity of an
immunoconjugate of RedituxTM were investigated in vitro
using RAMOS cells [58]. The immunoreactivity of the
mAb conjugate, as reported by the authors, showed high
and specific binding ability to target cells (nonspecific
binding showed \2% of the total radioactivity). The
immunoreactive fraction was reported as r = R2
0.9952 = 0.7984, where R = 0.8957. The radiolabeled
doses of the mAb conjugate were reported to be pyrogen
free. The bacterial endotoxin level was\0.1 EU/mL (the
authors reported a permissible limit of \0.5 EU/mL;
Table 4). The Thakral et al. study [58] assessed human
subjects as well, and thus underwent quality assessment
using the Downs and Black instrument. The study was
considered to be of good quality.
As described previously, the physicochemical properties
of RedituxTM were evaluated and compared with
Kikuzubam and rituximab [57]. The sequence compara-
bility of RedituxTM to both comparators was confirmed
using peptide mapping (RP-HPLC). Results of the chemi-
cal composition analysis showed heterogeneity of Redi-
tuxTM (compared with rituximab and Kikuzubam) in
theoretical mass due to the C-terminal lysine content.
Significant differences were observed for both RedituxTM
and Kikuzubam versus rituximab with respect to charge
variants, as determined by CEX and HIC. The structure of
RedituxTM (determined by DSC and MALS) and purity
(determined by CGE and SEC) were said to be similar
compared with both the originator and Kikuzubam.
Mekhssian et al. developed a workflow to aid in a more
comprehensive biosimilar comparability assessment using
high-resolution MS methodologies [65]. Although this
study was not aimed at the characterization of RedituxTM,
it was utilized as a prototypic agent along with the origi-
nator, and some analyses of the data are relevant to this
review. Three main glycoforms, G0F, G1F, and G2F, were
observed in the mass spectra corresponding to the Fc/2
fragment of both RedituxTM and rituximab, with variations
in their corresponding ratios. The authors observed that the
C-terminal lysine (heavy chain) was completely clipped for
rituximab and only partially clipped for RedituxTM.
Moreover, the presence of a light chain without N-terminal
pyroglutamate formation was identified only in RedituxTM.
The authors reported on the suitability of IdeS digestion as
a method to generate mAb fragments that are more
amenable for LC separation. The authors postulated that
the addition of guanidine hydrochloride (GdHCl) in turn
permits the complete reduction of disulfide bridges.
Results of a comparability study by Lin et al. indicated
similar structural profiles for rituximab-US and rituximab-
EU [66]. However, significant differences were reported
between rituximab-USA/-EU and RedituxTM as delineated
by imaged capillary electrophoresis, capillary elec-
trophoresis, and CEX-HPLC methods [66].
3.6 Quality Assessment of the Studies
The quality of analytical and cell-based studies, including
abstract publications of analytical and animal studies, could
not be evaluated as validated tools to assess the risk of bias
for these types of studies or publications were unavailable at
the time of the analysis. Thirteen studies were not evaluated
[19–23, 27, 31–33, 57, 64–66]. An additional two published
abstracts were found to be trial protocols and thus were not
eligible for quality assessment [36, 55].
Two RCTs were assessed using the NICE STA manu-
facturer’s template and Jadad scoring tool (Supplementary
Fig. S3) [40, 43]. Both studies were considered to be of
excellent quality. Using the NICE STA assessment criteria,
although both studies were randomized, only one study
provided information to assess the randomization process
(Yin et al. [43] did not). Despite the lack of details for
randomization in the Yin et al. study, both RCTs were
reported as being concealed and blinded. However, details
of the blinding method were not provided in Yin et al. [43].
Patient withdrawals, outcome selection, reporting bias, and
statistical analyses were appropriately reported in both
studies according to the NICE STA criteria.
The two RCTs were also evaluated using the Jadad
scoring tool, with Wisman et al. [40] (5 points) reporting on
the randomization and method, blinding and methodology,
and withdrawals and dropouts (Supplementary Fig. S3),
whereas Yin et al. [43] (3 points), as mentioned above, failed
to report on the method of randomization and blinding. Two
observational studies were assessed using the Downs and
Black scoring tool (Supplementary Fig. S4) [58, 60]. Of
these, both were considered to be of good quality. Roy et al.
scored 16 points from a maximum of 27 points [60], while
Thakral et al. scored 13 points [58].
Word count in abstracts from conference proceedings
and meetings is restricted, and thus abstracts generally
provide limited information on study methodologies and
outcomes. For this reason, the Downs and Black instrument
was adapted to assess the quality of the 11 identified
abstracts for original studies (Supplementary Fig. S5)
[16, 45–47, 50–54, 62, 63]. The average score for abstract
publications was 8.5 out of a possible 12 points. The total
score was fair quality (3–4) for one study [62], good quality
(5–8) for two studies [50, 63], and excellent quality (9–12)
for eight studies [16, 45–47, 51–54]. The majority of studies
published as conference abstracts were of good or excellent
quality (90.9%). Three animal studies were assessed using
SYRCLE’s risk of bias tool (Supplementary Fig. S6)
[24, 29, 34]. The three studies were of moderate quality.
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3.7 Weight and Breadth of Evidence
for Biosimilarity
The available comparative data from full-text publications
of RCTs are currently limited. In addition, the only post-
marketing/observational studies that were identified were
for intended copy RedituxTM. Biosimilarity (based on
combined evidence from all related published studies) was
graded as identical, highly similar, similar, and dissimilar,
which was directly inferred from the conclusions of the
study authors (Table 5). For biosimilars, based on study
author conclusions from the literature at the time the search
was undertaken, the current data from clinical and non-
clinical studies suggest a moderate to high degree of sim-
ilarity between the described biosimilars and their
originators (Table 5). The degree of biosimilarity is
ultimately determined by regulatory authorities and is
based on the totality of evidence, which includes data on
molecular and functional characterization, other nonclini-
cal data, and the safety, PK, immunogenicity, and efficacy
clinical trial data. However, given that regulatory submis-
sions are not publicly available and the full data set therein
cannot be systematically reviewed, the authors have instead
based all analysis on information from the peer-reviewed
literature.
The total number of studied variables and total reported
patient numbers were identified from analytical/nonclinical
and clinical studies, respectively. These parameters were
then mapped (Fig. 2a, b) against the degree of similarity
(as observed by the study author) in order to depict the
depth of the research programs and the overall quantity of
available evidence for each agent.


















Bevacizumab ABP 215 (Amgen, USA) 44*** 44 44 NA NA
BCD-021 (Biocad, Russia) NA NA 44 44 NA
PF-06439535 (Pfizer, USA) 4 or 44 4 NA NA NA
RPH-001 (Alphamab, China/R-Pharm,
Russia)
NA 4 NA NA NA
Rituximab BCD-020 (AcellBiaTM; Biocad, Russia) NA NA NA 44 NA
GP2013 (Sandoz, Switzerland) 444 4 NA NA NA
PF-05280586 (Pfizer, USA) 44 or
444
44 NA NA NA
RTXM83 (mAbxience, Switzerland) 4 4 4 NA NA
SAIT101 (Samsung, South Korea) NA NA 44 NA NA
1B8 (Center of Molecular Immunology,
Cuba)
NA 4 NA NA NA
Intended Copies
of Rituximab
Kikuzubam (Probiomed, Mexico) 3 or
444
44 NA NA NA
RedituxTM (Dr. Reddy’s Laboratories,
India)
3 4 NA NA 4
Trastuzumab BCD-022 (Biocad, Russia) NA NA 44 NA NA
CT-P6 (Celltrion, South Korea) NA NA 44 44 NA
FTMB (ABP 980; Allergan, USA/
Amgen, USA/Synthon, the
Netherlands)
NA NA 4 NA NA
PF-05280014 (Pfizer, USA) 44 or
444
44 44 NA NA
NA not applicable, evidence from published studies not available, PK pharmacokinetics
4 Similar (based on combined evidence from all related published studies)
44 Highly similar (based on combined evidence from all related published studies)
444 Identical (based on combined evidence from all related published studies)
3 Dissimilar (based on combined evidence from all related published studies)
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BCD-021 (BEV) BCD-020 (RTX)
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GP2013 (RTX)
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Studies (n = 16) of the proposed biosimilars and
intended copies that were identified included 2514 patients
or healthy subjects (Fig. 2a). Biosimilars CT-P6 and PF-
05280014 reported the largest combined study populations
from PK/safety and comparative efficacy/safety studies
[649 and 1015 (two planned studies) patients, respectively].
Based on clinical reports (Fig. 2a), development candidates
FTMB and RTXM83 were reported to be similar to their
originators. All other development candidates were repor-
ted by study authors to be highly similar, based on clinical
studies.
The extent of reported information varied greatly across
studies when considering the breadth of data available for
preclinical studies (based on number of variables reported
from structural, functional, and nonclinical studies) for
named biosimilars (Fig. 2b). PF-05280586 (rituximab), PF-
05280014 (trastuzumab), and GP2013 (rituximab) all had
published data on a larger number of investigated variables
for analytical and nonclinical biosimilarity (ranging from
29 to 54), compared with the other development candi-
dates, which published on average only five variables
across their preclinical programs, as reported in the liter-
ature. Findings from Flores-Ortiz et al. [57] revealed
heterogeneity with respect to MS and CEX data for
intended copy Kikuzubam. All other variables (DSC
analysis, peptide mapping, glycan quantification, etc.)
were, however, reported to be the same. Thus the posi-
tioning on the x-axis (Fig. 2b) was determined to be both
dissimilar and identical across selected variables. Although
the conclusions put forward by study authors were that the
majority of molecules exhibited biosimilarity to their
originator, comparative data were not provided for all
attributes studied.
3.8 Non-empirical Data
A limited number of non-empirical publications that ref-
erenced a named biosimilar were retrieved overall. These
results are shown in Supplementary Table S5. A large
percentage of these studies described approaches or
methodologies for the characterization and development of
biosimilars, as well as how to demonstrate biosimilarity
with the originator molecule [67–71]. Additional studies
provided examples of biosimilars and opinions on regula-
tory aspects of biosimilar development [72–80].
3.9 Planned and Ongoing Trials of Bevacizumab,
Rituximab, and Trastuzumab Biosimilars
The results of the ClinicalTrials.gov search (conducted
September 21, 2015) are presented in Supplementary
Table S6. A total of six oncology clinical trials were
identified for proposed biosimilars of bevacizumab, one of
which was complete at the time of analysis. PF-06439535
represented the most commonly studied bevacizumab
biosimilar (two trials identified, one PK/safety study
complete). Comparative efficacy and safety studies were
reportedly active for ABP 215 and for BCD-021 at the time
of analysis. The search also identified additional oncology
biosimilars not yet appearing in the published literature.
These were bevacizumab biosimilars SB8 (Samsung
Bioepis) and BEVZ92 (mAbxience/Laboratorio Elea/
LIBBS).
For proposed biosimilars of rituximab, six trials, all in
lymphoma, were reported. CT-P10 (Celltrion) had the
highest number of studies (two comparative efficacy and
safety trials identified, one actively recruiting). Single
comparative efficacy and safety studies were also listed on
the ClinicalTrials.gov registry for BCD-020, GP2013, PF-
05280586 and RTXM83.
Within oncology and compared across all originator
classes, trastuzumab biosimilars appeared most frequently
in nine studies (two PK/safety in healthy subjects, one PK/
safety study in patients with BC, and six comparative
safety/efficacy trials). Of the trastuzumab biosimilars, Pfi-
zer’s PF-05280014 had the most studies listed (one PK/
safety study in healthy subjects, and two further studies in
BC patients [55, 56]), followed by Celltrion’s CT-P6 (two
comparative efficacy/safety studies). The search also
identified a novel trastuzumab biosimilar, SB3 (Samsung
Bioepis), not yet appearing in the published literature at the
time of review.
3.10 Publishing Trends on Biosimilars
3.10.1 Journals
A total of 58 unique journals publishing material on
biosimilars in oncology that met our inclusion criteria were
identified during this review (23 of which published
empirical studies; Supplementary Table S7). The top
publishing journal was mAbs, which has published seven
articles since 2010, five of which were published between
2013 and 2015. Before 2005, no journal articles relevant to
Fig. 2 Biosimilarity and a total number of healthy subjects or
patients for proposed biosimilars and ICs in clinical trials; and
b breadth of data for proposed biosimilars and ICs in analytical and
nonclinical studies. Totality of evidence from all available published
studies (up to September 3, 2015) was used to assess ‘‘degree of
similarity’’ for proposed biosimilars and ICs, and is based on the
original conclusions made by the study authors. The scale of reference
used by each author was not accounted for, as this was not uniformly
reported in the literature. * based on author interpretation of study
data, Kikuzubam exhibits, in some cases, dissimilar and, in other
cases, identical physicochemical characteristics compared with the
originator. BEV bevacizumab, IC intended copy, RTX rituximab, TRA
trastuzumab
b
Biosimilars for Cancer: A Systematic Review of Published Evidence 29
the topic of mAbs or fusion protein biosimilars were
published relevant to the field of oncology. The greatest
number of articles was published in 2013 (n = 8), of which
mAbs, Seminars in Oncology, and Annals of Oncology
published two each. Since 2011 (up to and including 2014),
the number of publications per year has reached similar
totals (n = 5, 5, 8, 4, and 6 for 2011, 2012, 2013, 2014, and
2015, respectively).
The mAbs journal published the greatest number of
empirical studies in oncology (n = 7), all of which were
published in the years 2011–2015 (three were published
between January and September in 2015).
3.10.2 Congresses
A total of 27 unique congresses were identified as pub-
lishing abstracts of mAb biosimilars relevant to oncology
between 2007 and August 2015. Between January and
August 2015, 14 abstracts were identified, highlighting the
increasing interest in biosimilars for oncology among
academic and industry professionals.
The top three congresses identified with the highest
number of published abstracts were the American Associ-
ation of Pharmaceutical Scientists National Biotechnology
Conference (AAPS-NBC) (n = 13), the American Society
of Clinical Oncology (ASCO) Annual Meeting (n = 11),
and the American Society of Hematology (ASH) Annual
Meeting (n = 4). The diverse range of congresses identi-
fied [i.e., scientific (analytical), oncology specific, regula-
tory/payer focused] provides evidence of the importance
researchers and manufacturers put on disseminating their
data to a broad audience. Before 2007, no congress
abstracts relevant to the topic of mAb biosimilars in
oncology were identified. Among the top identified con-
gresses (and up to the last complete year, 2014), the highest
number of abstracts was published in 2013 (n = 18), a
threefold rise from the previous year (n = 6). In 2013, the
congress with the greatest number of relevant published
abstracts was the AAPS-NBC (n = 6), followed by ASCO
(n = 2), the International Society of Pharmacovigilance
(n = 2), the European Cancer Congress (n = 2), the
American Association for Cancer Research (n = 2), and
the European Society for Animal Cell Technology (n = 2)
(Supplementary Table S8).
4 Discussion
4.1 Challenges Relevant to Biosimilar Development
Identified in the Literature
While biosimilars will eventually play a greater role in the
care of patients with cancer, there remain challenges that
will temper their immediate impact. We identified several
surveys in our review of the literature that highlight some
of these challenges. For example, a survey published in
2013 of 400 healthcare professionals (including oncolo-
gists, nurses, and pharmacists) demonstrated that most
participants had a lack of understanding of the regulatory
pathways for biosimilars, as well as a lack of familiarity
with biosimilars in the current drug pipeline [81]. A survey
of 277 healthcare providers (including physicians, nurses,
and pharmacists) conducted by the National Comprehen-
sive Cancer Network (NCCN) showed similar results [6].
When asked about the level of interest in prescribing,
dispensing, or administering biosimilars in their practices,
21% of physicians, 31% of nurses, and 26% of pharmacists
said they needed more information on biosimilars to make
a decision. Among the NCCN recommendations made by
the multidisciplinary Biosimilars Working Group was a
recommendation for healthcare professionals and policy
makers to be educated on biosimilars [6]. The areas that
respondents most wanted information on were related to
comparative clinical endpoints (safety and efficacy), PK
similarity (absorption, distribution, metabolism, and elim-
ination), chemical/physical similarity, and guideline and
compendia inclusion.
In addition to the need for robust educational programs
on biosimilar therapies, several additional factors may
influence integration of biosimilars into oncology practices
[82]. These include the choice of patient population for
efficacy evaluation, the choice of efficacy endpoints,
extrapolation of indication, post-approval safety monitor-
ing for immunogenicity, and interchangeability and auto-
matic substitution. Physicians, payers, and other healthcare
stakeholders will all influence the uptake and widespread
adoption of biosimilars in clinical practice. As indicated in
the NCCN survey, oncologists want access to the data used
to support FDA approval of biosimilars, and furthermore,
they need to be confident in the evidence supporting
biosimilarity [6]. It is therefore incumbent on manufac-
turers to provide as much transparency in their develop-
ment programs as possible.
4.2 Biosimilars
The majority of data comparing an investigational
biosimilar with the originator in oncology imply a mod-
erate to high degree of similarity compared with the orig-
inator products bevacizumab and trastuzumab, as inferred
from study author conclusions (Table 5; Fig. 2a, b). This
trend appears to be reflected throughout the stages of
biosimilar development, showing that the biosimilar of
interest showed high similarity at the structural level (as
characterized by biochemical methods), displayed accept-
able levels of biological activity (i.e., functional similarity)
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in vitro, and met the required PK thresholds in vivo (usu-
ally in mice or monkeys; Table 5; Fig. 2a, b).
The evidence generated in preclinical stages supports
progression to clinical stages of development. Of the pro-
posed biosimilars identified in this review, a number of
molecules have followed the same logical path, including
Amgen’s ABP 215 (bevacizumab), which, at the time of
review, was at more advanced stages of clinical develop-
ment in advanced NSCLC, having shown a high degree of
structural similarity to bevacizumab along with achieving
the desired outcomes (performing at the level of the orig-
inator or better) in animal models and in early safety and
PK trials in humans. Pfizer’s PF-06439535 (bevacizumab)
was also pursuing the same course, with comparative
safety/efficacy trials underway in NSCLC, having satisfied
all data requirements during its preclinical phase.
For proposed rituximab biosimilars in development for
oncology, GP2013 (Sandoz), PF-05280586 (Pfizer), and
RTXM83 (mAbxience) were reportedly in active compar-
ative safety/efficacy studies in lymphoma. Both molecules
have shown adequate degrees of similarity to rituximab
during preclinical stages of development. Various press
releases (in 2012) alluded to the halt in development of
SAIT101 (Samsung), owing to concerns over biosimilar
regulations in several markets [83]. Results in a PK/safety
study of SAIT101 in patients with lymphoma were reported
in a single publication in 2014; however, no publications
were identified before or since then.
For all proposed biosimilars, it should be noted that the
number and quality of studies providing evidence of
structural and functional similarity at the preclinical phase
may not necessarily be sufficient to predict behaviors or
performance in humans. Manufacturers are required to
provide high-quality evidence of comparable PK/PD and
comparative efficacy and safety outcomes (including a
comprehensive immunogenicity assessment) for these
biosimilars in well-designed trials if they are to satisfy the
requirements of the EMA and FDA for approval.
According to this review, three of Biocad’s molecules
[BCD-020 (rituximab), BCD-021 (bevacizumab), and BCD-
022 (trastuzumab)] have entered the clinical development
phase without published evidence of underlying structural and
functional similarity to their originators, for which a prelim-
inary nonclinical assessment is required. While the authors
concede that unpublished data may exist for these molecules,
the intent of this research was to uncover the gaps in the
literature that may contribute to stakeholder uncertainty about
the depth and breadth of evidence underpinning these mole-
cules. In the case of the trastuzumab biosimilars, at the time
of this review, PF-05280014 (Pfizer) was the only molecule
that had published data from all nonclinical and clinical
stages. CT-P6 (Celltrion) was being investigated in PK/safety
and comparative safety/efficacy trials in metastatic BC;
FTMB (Amgen/Allergan/Synthon) had data from PK/safety
trials (in healthy subjects), but plans for further trials were not
reported; and the aforementioned BCD-022, at the time of the
analysis, was being investigated in a comparative safety/ef-
ficacy study (in metastatic BC).
4.3 Intended Copies
In addition to the biosimilars identified in the literature,
the authors also reviewed available data for intended
copies. The extent of available data between proposed
biosimilars and intended copies differs between products
[7]. Nonclinical studies on intended copy Kikuzubam
(Probiomed) have, thus far, provided some evidence of its
structural and functional similarity to rituximab. How-
ever, Kikuzubam was marketed as a biosimilar or
‘‘biocomparable’’ in Mexico, gaining approval without
published comparative clinical studies to provide evi-
dence of its safety or efficacy. In 2012, the Mexican
Pharmacovigilance Program issued a warning of ana-
phylactic reactions that occurred in several patients.
Subsequently, Kikuzubam was withdrawn from the
market by the regulatory authority, owing to the docu-
mented anaphylactic reactions and the lack of clinical
data [84]. Some countries are now only just beginning to
establish formal regulatory guidelines for the approval of
biosimilars to cover requirements for preclinical, clinical,
or other analyses that should be used to demonstrate the
safety, quality, and effectiveness of a biosimilar (includ-
ing studies required for immunogenicity and AEs), as well
as demonstration of similar modes of action or PD prop-
erties to that of the originator. Other countries are yet to
provide any guidelines.
RedituxTM (Dr. Reddy’s Laboratories) represents a fur-
ther example of an intended copy that has been marketed in
Latin American markets, India, and Iran, without rigorous
data to indicate structural or functional similarity or clini-
cal effectiveness compared with rituximab. Based on the
totality of evidence from studies identified during this
review, RedituxTM shows heterogeneity with respect to
structure, and RCTs are lacking [84, 85]. Although several
observational studies have been reported for RedituxTM,
only one study (retrospective in design) included rituximab
as a comparator.
A clear distinction must therefore be made with regard
to appropriate terminology for these products, subject to
the level and quality of evidence on each, such that they
may be easily classified into one of the following cate-
gories: ‘‘approved biosimilars’’ (from a regulatory stand-
point), ‘‘proposed biosimilars’’ (i.e., they are currently in
development, but not yet approved by regulatory authori-
ties), and ‘‘intended copies’’ (i.e., have not undergone
rigorous comparative evaluations according to the WHO
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recommendations, but are being commercialized in some
countries). As is evident from this review, manufacturers
and researchers do not always clearly state whether they
are developing a true biosimilar, or whether they are
planning to introduce an intended copy (and appropriately
name it as such).
4.4 Knowledge Gaps
Biosimilar products require comprehensive testing to
ensure biosimilarity in terms of PK/PD, safety, and effi-
cacy. This is to ensure patients are receiving efficacious
treatment and are not being put at unnecessary risk of
treatment complications, as has occurred in the case of
some intended copies being commercialized in emerging
markets without having undergone rigorous comparative
evaluations according to the WHO recommendations [84].
A perceived advantage of biosimilars is their potential to
reduce the acquisition cost of cancer drugs, thereby
increasing affordability and patient access. Thus, economic
factors will influence the use of these drugs in clinical
practice. It has been estimated that biosimilars will cost
20–40% less in the USA, while in the EU, savings of
10–35% have been reported [7]. This is in contrast to the
typical 70–80% discount associated with small-molecule
generic drugs [7]. Evaluation of cost and potential cost
savings will need to be performed by oncologists, institu-
tions, and payers. From a broader societal impact, cost-
effectiveness analyses will need to be performed in order to
manage the differences in perceived value of these drugs
when comparing the payer’s versus the patient’s and
caregiver’s perceptions. In addition, pharmacovigilance
and risk management, as well as safety and tolerability
considerations, will need to be taken into account when
assessing the value of biosimilars.
4.5 Limitations of this SLR
Several limitations of the study should be noted. These
include the potential of database searches not capturing all
terms related to oncology or mAb biosimilars. Also, the
determination of ‘‘proposed biosimilar’’ versus ‘‘intended
copy’’ is limited by the inability to discern the intentions of
manufacturers with development candidates. The term
‘‘proposed biosimilar’’ is employed in this analysis as a
blanket term for all development candidates pending final
determination of their status as biosimilars. In addition, a
relatively small number of selected conference proceedings
were searched. Thus, it is possible that data presented in
other conference proceedings may not have been included
in this analysis. Furthermore, at the time of analysis, lim-
ited outcomes data were available from published
conference abstracts only, with no full-text publications
available at the time of the review.
The search for clinical trials was done using the Clini-
calTrials.gov results database; no other clinical trial reg-
istries were used in this analysis. Therefore, it is possible
that trials not registered on ClinicalTrials.gov but regis-
tered on other clinical trial databases may have been
missed.
The degree of biosimilarity, as determined by regulatory
authorities, is based on the totality of evidence approach,
which includes data on molecular and functional charac-
terization, other nonclinical data, and the safety, PK,
immunogenicity, and efficacy clinical trial data. We did not
attempt to assess the agents against the criteria used by
regulatory authorities, but instead based our analysis on the
totality of evidence in the public domain, with biosimilarity
determined on the basis of study authors’ conclusions.
Consequently, our analysis is based on the scale of refer-
ence (i.e., ‘‘identical,’’ ‘‘highly similar,’’ ‘‘similar,’’ or
‘‘dissimilar’’) used by the study authors. Conclusions on
biosimilarity were also drawn collectively from a variety of
clinical study types [e.g., RCTs and observational
(prospective or retrospective) studies], without accounting
for any variation in the overall quality of evidence provided
by each study type.
One of the original aims of our research was to identify
gaps in the published literature. The results presented
therefore contain only the outcomes data and statistical
comparisons available from the published abstracts or full-
text articles retrieved from the search. Thus, the informa-
tion collated may not be representative of the full extent of
data available for each study, only that which has been
published. It should additionally be noted that the search
strategy was designed to capture only articles published by
MEDLINE or Embase indexed journals. Therefore,
studies published by non-indexed journals were not inclu-
ded. A full Internet search of all online content was not
included in the methodology.
As this review represents a cross-sectional analysis of
available published evidence over a defined period, the
molecules reviewed were at various stages of development
and therefore cannot be compared like for like. Since
completion of this review, the authors have identified new
biosimilar studies in oncology. These include clinical trials
for ABP798 (rituximab; Amgen; CD20? NHL) and for
HLX01 (rituximab; Shanghai Henlius Biotech; CD20?
DLBCL). The JASMINE study is a randomized, double-
blind study assessing the safety and efficacy of ABP798
compared with rituximab in patients with CD20? NHL.
The safety and efficacy of HLX01 is being compared with
rituximab in combination with CHOP in previously
untreated subjects with CD20? DLBCL.
32 I. Jacobs et al.
5 Conclusions
This SLR collates and summarizes all published evidence
up to September 2015 on named biosimilars and intended
copies of originator mAbs that have been developed in the
field of oncology. The review identified biosimilars for the
marketed biologics bevacizumab, trastuzumab, and ritux-
imab, and many of these biosimilar molecules are in late-
stage clinical development. Intended copies in develop-
ment for rituximab were also identified.
At present, robust evidence of outcomes for mAb
biosimilars in cancer, including data from comparative
efficacy and safety trials, is not yet substantially available in
the published literature. The authors acknowledge that there
are a number of planned and ongoing clinical trials that will
help inform the current knowledge gaps. While biosimilar
treatments are expected to reduce drug costs and increase
patient access to much-needed therapies, the potential
impact of these drugs in oncology is currently unclear. Only
when oncology biosimilars are approved and adopted in
routine clinical practicewill their impact be fully recognized.
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